Therefore, we propose that QRHXF may suppress M2 macrophage polarization, enhance T cell-mediated innate antitumor immune response, and potentiate ICB for NSCLC treatment via TREM2 and the PI3K/AKT/STAT6 pathways. The gene discussed is STAT6; the disease is non-small cell lung carcinoma.